Literature DB >> 12102656

Novel human ZAKI-4 isoforms: hormonal and tissue-specific regulation and function as calcineurin inhibitors.

Xia Cao1, Fukushi Kambe, Takashi Miyazaki, Devanand Sarkar, Sachiko Ohmori, Hisao Seo.   

Abstract

We identified a thyroid hormone [3,5,3'-tri-iodothyronine (T(3))]-responsive gene, ZAKI-4, in cultured human skin fibroblasts. It belongs to a family of genes that encode proteins containing a conserved motif. The motif binds to calcineurin and inhibits its phosphatase activity. In the present study, we have demonstrated three different ZAKI-4 transcripts, alpha, beta1 and beta2, in human brain by 5'- and 3'-RACE (rapid amplification of cDNA ends). The alpha transcript was identical with the one that we originally cloned from human fibroblasts and the other two are novel. The three transcripts are generated by alternative initiation and splicing from a single gene on the short arm of chromosome 6. It is predicted that beta1 and beta2 encode an identical protein product, beta, which differs from alpha in its N-terminus. Since alpha and beta contain an identical C-terminal region harbouring the conserved motif, both isoforms are suggested to inhibit calcineurin activity. Indeed, each isoform associates with calcineurin A and inhibits its activity in a similar manner, suggesting that the difference in N-terminus of each isoform does not affect the inhibitory function on calcineurin. An examination of the expression profile of the three transcripts in 12 human tissues revealed that the alpha transcript is expressed exclusively in the brain, whereas beta transcripts are expressed ubiquitously, most abundantly in brain, heart, skeletal muscle and kidney. It was also demonstrated that human skin fibroblasts express both alpha and beta transcripts, raising the question of which transcript is up-regulated by T(3). It was revealed that T(3) markedly induced the expression of alpha isoform but not of beta. This T(3)-mediated increase in the alpha isoform was associated with a significant decrease in endogenous calcineurin activity. These results suggest that the expression of ZAKI-4 isoforms is subjected to distinct hormonal as well as tissue-specific regulation, constituting a complex signalling network through inhibition of calcineurin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12102656      PMCID: PMC1222895          DOI: 10.1042/BJ20011797

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  GenBank.

Authors:  D A Benson; I Karsch-Mizrachi; D J Lipman; J Ostell; B A Rapp; D L Wheeler
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  High-resolution mapping of mammalian genes by in situ hybridization to free chromatin.

Authors:  H H Heng; J Squire; L C Tsui
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

3.  Human BAC ends.

Authors:  S Zhao
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

4.  Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy.

Authors:  M Shimoyama; D Hayashi; E Takimoto; Y Zou; T Oka; H Uozumi; S Kudoh; F Shibasaki; Y Yazaki; R Nagai; I Komuro
Journal:  Circulation       Date:  1999-12-14       Impact factor: 29.690

5.  Modes of DAPI banding and simultaneous in situ hybridization.

Authors:  H H Heng; L C Tsui
Journal:  Chromosoma       Date:  1993-05       Impact factor: 4.316

6.  A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling.

Authors:  B Rothermel; R B Vega; J Yang; H Wu; R Bassel-Duby; R S Williams
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

7.  A new gene family including DSCR1 (Down Syndrome Candidate Region 1) and ZAKI-4: characterization from yeast to human and identification of DSCR1-like 2, a novel human member (DSCR1L2).

Authors:  P Strippoli; L Lenzi; M Petrini; P Carinci; M Zannotti
Journal:  Genomics       Date:  2000-03-15       Impact factor: 5.736

8.  DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways.

Authors:  J J Fuentes; L Genescà; T J Kingsbury; K W Cunningham; M Pérez-Riba; X Estivill; S de la Luna
Journal:  Hum Mol Genet       Date:  2000-07-01       Impact factor: 6.150

9.  FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin.

Authors:  S J O'Keefe; J Tamura; R L Kincaid; M J Tocci; E A O'Neill
Journal:  Nature       Date:  1992-06-25       Impact factor: 49.962

10.  Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A.

Authors:  D A Fruman; C B Klee; B E Bierer; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

View more
  20 in total

1.  Distinct ontogenic and regional expressions of newly identified Cajal-Retzius cell-specific genes during neocorticogenesis.

Authors:  Hiroshi Yamazaki; Mariko Sekiguchi; Masako Takamatsu; Yasuto Tanabe; Shigetada Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-27       Impact factor: 11.205

2.  Chronic expression of RCAN1-1L protein induces mitochondrial autophagy and metabolic shift from oxidative phosphorylation to glycolysis in neuronal cells.

Authors:  Gennady Ermak; Sonal Sojitra; Fei Yin; Enrique Cadenas; Ana Maria Cuervo; Kelvin J A Davies
Journal:  J Biol Chem       Date:  2012-03-02       Impact factor: 5.157

3.  Identification of a peptide fragment of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo.

Authors:  Betty Chan; Garrett Greenan; Frank McKeon; Tom Ellenberger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-30       Impact factor: 11.205

4.  The RCAN carboxyl end mediates calcineurin docking-dependent inhibition via a site that dictates binding to substrates and regulators.

Authors:  Sara Martínez-Martínez; Lali Genescà; Antonio Rodríguez; Alicia Raya; Eulàlia Salichs; Felipe Were; María Dolores López-Maderuelo; Juan Miguel Redondo; Susana de la Luna
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-30       Impact factor: 11.205

5.  Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis.

Authors:  Carsten W Lederer; Antonietta Torrisi; Maria Pantelidou; Niovi Santama; Sebastiano Cavallaro
Journal:  BMC Genomics       Date:  2007-01-23       Impact factor: 3.969

6.  Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.

Authors:  Gennady Ermak; Karl J Hench; Kevin T Chang; Sean Sachdev; Kelvin J A Davies
Journal:  J Biol Chem       Date:  2009-03-06       Impact factor: 5.157

7.  Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibits angiogenesis.

Authors:  Lila K Gollogly; Sandra W Ryeom; Sam S Yoon
Journal:  J Surg Res       Date:  2007-07-05       Impact factor: 2.192

8.  Phosphorylation of calcipressin 1 increases its ability to inhibit calcineurin and decreases calcipressin half-life.

Authors:  Lali Genescà; Anna Aubareda; Juan J Fuentes; Xavier Estivill; Susana De La Luna; Mercè Pérez-Riba
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

9.  Complexity of bidirectional transcription and alternative splicing at human RCAN3 locus.

Authors:  Federica Facchin; Lorenza Vitale; Eva Bianconi; Francesco Piva; Flavia Frabetti; Pierluigi Strippoli; Raffaella Casadei; Maria Chiara Pelleri; Allison Piovesan; Silvia Canaider
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

10.  Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.

Authors:  Jose R Pineda; Raúl Pardo; Diana Zala; Hua Yu; Sandrine Humbert; Frédéric Saudou
Journal:  Mol Brain       Date:  2009-10-27       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.